How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

732 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Effects of Cinnamon Supplementation on Glucose Metabolism in Patients With Pre-diabetes

or hypersensitivity to any of the ingredients in the test products. Cognitive impairment or any other reason to expect the patient would have difficulty complying with study protocol Excessive alcohol intake defined as greater than 3 units of alcohol per day. Use of weight loss drugs (e.g., lorcaserin [Belviq]; phentermine/topiramate [Qsymia], liraglutide [Saxenda], Xenical [orlistat], Meridia [sibutramine], Acutrim [phenylpropanol-amine], or similar over-the-counter medications) within 3 months of the screening

2017 Clinical Trials

102. Ultrasound Assessment of the Adventitia, Extra-media (EMT) and Veia Jugularis Interna Thickness

, or participation within the last 3 months, in an organised weight loss programme (or within the last 3 months) Current or history of treatment with medications that may cause significant weight gain for at least 3 months before this trial Current use or use within three months before this trial of GLP-1 receptor agonist, pramlintide, sibutramine, orlistat, zonisamide, topiramate, or phentermine Type 1 diabetes Type 2 diabetes treated with glucose-lowering drugs other than metformin Alloplasty in target knee

2017 Clinical Trials

103. A Phase IV Study in Drug-Naive Patients With T2DM in China

affect the interpretation of efficacy or safety data. History of bone fracture secondary to diagnosed severe osteoporosis. Currently unstable or serious cardiovascular, renal, hepatic, hematologic, oncologic, endocrine, psychiatric, or rheumatic diseases as judged by the Investigator. Replacement or chronic systemic corticosteroid therapy, defined as any dose of systemic corticosteroid taken for >4 weeks within 3 months before enrollment visit. Administration of sibutramine, phentermine, orlistat

2017 Clinical Trials

104. Effect of Resistant Starch on Insulin Sensitivity and Beta Cell Function in Subjects With Prediabetes

, the administration of a treatment that may affect the interpretation of the efficacy and safety data. Treatment with any oral antidiabetic medicinal product and / or herbal preparations / non-prescription medicines that may affect glycemic control within 12 weeks prior to screening. Chronic treatment with oral or parenteral corticosteroids (> 7 consecutive days of treatment) within 4 weeks prior to screening. Treatment with weight-reducing agents (eg, orlistat, sibutramine, topiramate, bupropion) within the last

2017 Clinical Trials

105. Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses

requirements for chemotherapy, radiotherapy or hormonal therapy. Participants must be willing to discontinue any use of NSAIDs like aspirin or ibuprofen until the tumor is removed Participants cannot be taking the following medications because of major pharmacokinetic interactions with celecoxib while being enrolled in the study: Abciximab, Argatroban, Bivalirudin, Cilostazol, Dabigatran, Etexilate, Dipyridamole, Fondaparinux, Heparin, Lepirudin, Pemetrexed, Protein C, Rivaroxaban, Sibutramine, Ticlopidine

2017 Clinical Trials

106. Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System

populations (prisoners, etc.) will not be eligible to participate in this study. On weight loss drugs (i.e. orilistat (Xenical®), sibutramine (Meridia®), phenylpropanol-amine (Acutrim®)), or similar over-the-counter medications within 3 months of screening. Any surgery within 30 days of screening Those who currently donate blood, platelets, or plasma Any condition that, in the view of the PI or Co-I, places the subject at high risk or poor treatment and study compliance. We will also enroll 36 (...) ). Taking steroids or biologics: corticosteroids (prednisone); methotrexate, infliximib (Remicade®), etaneracept (Enbrel®); anakinra (Kineret®). Those who are currently donating blood, platelets, or plasma at the time of screening. Vulnerable populations (prisoners, etc.) will not be eligible to participate in this study. On weight loss drugs (i.e. orilistat (Xenical®), sibutramine (Meridia®), phenylpropanol-amine (Acutrim®)), or similar over-the-counter medications within 3 months of screening. Any

2017 Clinical Trials

107. Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

of the study Use of weight lowering medications (orlistat, sibutramine, rimonabant, phentermine) Clinically significant GI (Gastro-Intestinal) disease including inflammatory bowel disease, irritable bowel syndrome, celiac disease, dyspepsia, apparent diabetic gastro paresis, diabetic diarrhoea, or surgery of the gastro-intestinal tract (except appendectomy and cholecystectomy) Subjects who are sexually active and have not been surgically sterilised must be informed that they and their partner use a highly

2017 Clinical Trials

108. Fluorescent Imaging & Methylene Blue: Ureter Study

: Patient who is unable or unwilling to give informed consent Female participant who is pregnant, lactating or planning pregnancy during the course of the trial. Significant renal or hepatic impairment. Any patients with previous allergies to Methylene Blue Any patients at risk of serotonin syndrome, including those taking serotonin reuptake inhibitors (SSRIs) or serotonin reuptake inhibitors (e.g. duloxetine, sibutramine, venlafaxine, clomipramine, imipramine) Patients with glucose-6-phosphate

2017 Clinical Trials

109. J K Aronson – The Hitchhiker’s Guide to Clinical Pharmacology Part 2

Withdrawn Torcetrapib 2006 Cardiotoxicity Withdrawn Sibutramine 2010 Cardiotoxicity Withdrawn Rosiglitazone 2011 Cardiotoxicity Withdrawn Occasionally a drug may be withdrawn but then reintroduced for specific reasons or with specific monitoring. Examples include: clozapine, a dopamine D 2 receptor antagonist used to treat schizophrenia, which was withdrawn in 1985 because of neutropenia, but was then reintroduced in 1989 with a mandatory blood monitoring scheme, in order to detect neutropenia as soon

2016 CEBM blog

110. Ferulic acid lowers body weight and visceral fat accumulation via modulation of enzymatic, hormonal and inflammatory changes in a mouse model of high-fat diet-induced obesity (PubMed)

male Swiss mice, weighing 20-25 g (n=6-8 per group) were fed a normal diet (ND) or HFD, treated orally or not with either FA (10 mg/kg) or sibutramine (10 mg/kg) for 15 weeks and at the end of this period, the body weights of animals, visceral fat accumulation, plasma levels of glucose and insulin hormone, amylase and lipase activities, the satiety hormones ghrelin and leptin, and tumor necrosis factor-α (TNF-α) and monocyte chemoattractant protein-1 (MCH-1) were analyzed. Results revealed that FA (...) could effectively suppress the HFD-associated increase in visceral fat accumulation, adipocyte size and body weight gain, similar to sibutramine, the positive control. FA also significantly (P<0.05) decreased the HFD-induced elevations in serum lipid profiles, amylase and lipase activities, and the levels of blood glucose and insulin hormone. The markedly elevated leptin and decreased ghrelin levels seen in HFD-fed control mice were significantly (P<0.05) reversed by FA treatment, almost reaching

Full Text available with Trip Pro

2017 Brazilian Journal of Medical and Biological Research

111. Exogenous T3 toxicosis following consumption of a contaminated weight loss supplement (PubMed)

a weight loss product online from India which supposedly contained sibutramine. He provided one of the tablets and laboratory analysis confirmed the presence of T3 in the tablet. Full symptomatic resolution and normalised thyroid function ensued upon discontinuation of the supplement.Free tri-iodothyronine (T3) measurement may be useful in the presence of symptoms suggestive of thyrotoxicosis with discordant thyroid function tests.Thyroid uptake scanning can be a useful aid to differentiating exogenous

Full Text available with Trip Pro

2017 Endocrinology, diabetes & metabolism case reports

117. SNAP: a population health guide to behavioural risk factors in general practice

appropriate. For a small number of obese patients (BMI >30 or BMI >27 with other diseases) who do not respond, medical or surgical interventions may need to be considered. Drugs that may be added to education and behavioural interventions include orlistat and sibutramine for long term therapy, and phentermine and diethylpropion for short term use only. Small amounts of weight loss or lack of any increase can be viewed as successes with health gains likely. Any changes made must be able to be maintained

2014 The Royal Australian College of General Practitioners

119. Systematic review with meta-analysis: Orlistat reduces weight but its cost?effectiveness remains unclear

, sibutramine and … Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways. Copyright information: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to Read the full text or download the PDF: Subscribe Log in Log

2013 Evidence-Based Nursing

120. Obesity

- release daily dizziness, mild increase in blood pressure and heart rate excreted by kidneys; pregnancy category B; requires blood- pressure monitoring Sibutramine Meridia (Abbott) Approved for weight loss No Inhibition of norepinephrine and serotonin reuptake 5, 10, or 15 mg/day 5% Mild increase in blood pressure and heart rate (rarely more severe), palpitations Pregnancy category C; requires blood- pressure monitoring Orlistat Xenical (Roche); Alli (GlaxoSmithKline) Approved for weight loss No Lipase (...) Organisation, 2011 • Approved for short-term use only; limited data suggest these stimulants may be effective for > 10 years. SibutramineSibutramine is modestly effective in reducing weight, with differing effects on cardiovascular risk and various adverse effect profiles. • Treatment with sibutramine reduced body weight but not blood pressure. • Randomized trials have shown a 5% greater weight reduction in comparison with placebo (but only short-term trials have been carried out; administration

2011 World Gastroenterology Organisation

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>